Q BioMed Inc. (OTCQB: QBIO) CEO Provides Corporate
Overview in an Interview With Scrip Intelligence: Developments in Vascular Therapeutics
Mike Ward Global
Director of Content, Informa Pharma Insights discusses Q BioMed with Denis
Corin in San Francisco at the BioTech Showcase 2016
NEW
YORK, NY - February 29, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO),
a biotechnology acceleration company is pleased to share the recently published
video interview from the Biotech Showcase conference which took place in San
Francisco in January 2016.
In
the video, CEO Denis Corin is interviewed by Mike Ward, Chief Content Officer,
Datamonitor Healthcare & Scrip Intelligence at Informa. Denis discusses the
Q BioMed business strategy and recent corporate developments. Watch the
interview here: http://www.partnering360.com/insight/showroom/id/736
We
invite our shareholders and interested parties to subscribe to our email list
and stay informed on our website at http://www.qbiomed.com and follow us on
the social media feeds we use.
About Q BioMed Inc.
Q BioMed Inc. "Q" is a biomedical
acceleration and development company. We are focused on acquiring companies and
biomedical assets. Q is dedicated to providing these target companies and
assets, strategic resources, developmental support, and expansion capital to
ensure they meet their developmental potential enabling them to provide
products to patients in need.
Forward-Looking Statements:
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our growth strategy
and product development programs and any other statements that are not
historical facts. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could negatively
affect our business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from those
currently anticipated are: risks related to our growth strategy; risks relating
to the results of research and development activities; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract, integrate, and
retain key personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in
our SEC filings. We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward looking statements contained
herein to reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based, except as
required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Source: Q BioMed Inc.
Sign up for the free investor news and stock alerts:
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
QBIO has retained investorideas.com for PR, media, news publication and social
media effective February 5th for three months: two thousand five hundred per
month.
Additional info regarding BC Residents and global Investors:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
No comments:
Post a Comment